Patricia Grocott

Patricia currently leads a research programme which involves Co-Designing Medical Devices and Technologies with people who are vulnerable to skin breakdown.  The focus is on using individuals’ experiences of devices and healthcare systems to identify shortfalls and to work with device users, designers, engineers, materials specialists and industry to co-design devices and systems to meet personal needs and the needs of health care providers.

The programme includes co-creating and validating digital patient recorded outcome indicators and platforms for remote patient and clinician monitoring of recovery and deterioration in response to treatment and care, to enable troubleshooting interventions and routine data capture.

Evaluation of the performance and costs of novel devices is included in the programme using an N-of-1 research design to answer critical questions as to how, why, why not devices meet patients’ needs. Those that fall short of the standard defined in the patient recorded outcome indicators can be refined.

Patricia’s background is in hospice–based clinical nursing. The lack of suitable technologies and systems to care for patients with extensive skin breakdown in palliative and end of life care led to this academic, translational research career at King’s.

Presentation at the Optimising skin health and wound healing in palliative care settings specialist/service specific study day

Creating medical devices with the people that use them


In this presentation the programme of research involving co-design of medical devices and technologies with the people who need them will be outlined. The research methodologies and methods, which underpin the research will be presented including:

  • Participatory co-design with patients, carers, and clinicians: unmet need drive device design and development
  • Multidisciplinary research with designers, engineers, small to medium-sized manufacturers
  • N-of-1 feasibility and proof-of-concept tests of novel devices with patients and clinicians
  • TELER patient-recorded outcome measures of novel device performance, cost consequences analysis

The WEB (Woundcare for Epidermolysis Bullosa) project will be drawn on to illustrate the research, the outputs, and the impact.

Epidermolysis Bullosa (EB), a rare inherited and incurable condition. Severe forms of EB, such as Dystrophic Epidermolysis Bullosa, result in repeat blistering, extensive wounds, squamous cell carcinomas, complex and time-consuming wound care. The focus of the research projects is to reduce the burden of complex wound care by co-designing novel solutions with the patients.